Mountain View epilepsy device maker NeuroPace files to go public
March 25, 2021 at 09:54 AM EDT
NeuroPace said that the 575,000 adults in the United States with drug-resistant focal epilepsy that can be monitored with its device represent a market worth about $26 billion annually.
